Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 2/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 11/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 9/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 9/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 4/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 6/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20830062 | 0.88 | — | — | |
| SCHEMBL17976777 | 0.82 | S1PR1 (0.40) | PGDS1PR1S1PR3S1PR5S1PR2 | |
| SCHEMBL20830131 | 0.80 | MMP2 (0.31) | — | |
| SCHEMBL20830134 | 0.73 | CYP3A4 (0.36) | — | |
| SCHEMBL17976780 | 0.71 | PLA2G2A (0.35) | S1PR1S1PR3S1PR5S1PR2 | |
| SCHEMBL23897853 | 0.69 | — | — | |
| SCHEMBL15948704 | 0.67 | EPHX1 (0.35) | — | |
| SCHEMBL21418914 | 0.65 | S1PR1 (0.42) | S1PR1S1PR3S1PR5S1PR2S1PR4 | |
| SCHEMBL24371662 | 0.65 | S1PR1 (0.42) | S1PR1S1PR3S1PR5S1PR2S1PR4 | |
| SCHEMBL20830135 | 0.64 | CA1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230062181-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2023-03-02 | — | — | US | disclosed |
| US-11192914-B2 | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto | EMORY UNIVERSITY (US) | 2021-12-07 | — | — | US | disclosed |
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210308168-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-07 | — | — | US | disclosed |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2019-10-03 | — | — | US | disclosed |
| US-20190144484-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2019-05-16 | — | — | US | disclosed |
| US-20190085013-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2019-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192914-B2 | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto | PNP, NTPCR, TYMP | PGD 1127/4885S1PR1 380/4885S1PR3 393/4885 |
| US-20210308168-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, PRPF4, HPRT1 | PGD 3010/4885S1PR1 1499/4885S1PR3 1292/4885 |
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | PNP, TYMP, HPRT1 | PGD 1790/4885S1PR1 1430/4885S1PR3 1893/4885 |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | SLC28A1, PNP, SLC28A2 | PGD 2523/4885S1PR1 378/4885S1PR3 454/4885 |
| US-20190085013-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | PGD 1867/4885S1PR1 1296/4885S1PR3 1462/4885 |
| US-20190144484-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | TYMP, PNP, NTPCR | PGD 1867/4885S1PR1 539/4885S1PR3 497/4885 |
| US-20230062181-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | TYMP, NTPCR, PNP | PGD 1759/4885S1PR1 568/4885S1PR3 512/4885 |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | PNP, NTPCR, TYMP | PGD 1867/4885S1PR1 1296/4885S1PR3 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.